Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Cleveland Clinic's Cole Eye Institute receives $310,000 grant
Cleveland, OH-The Cleveland Clinic's Cole Eye Institute and biotechnology firm Arteriocyte Inc. have been awarded a $310,000 grant to study the treatment of eye disease.
Cleveland, OH-The Cleveland Clinic's Cole Eye Institute and biotechnology firm Arteriocyte Inc. have been awarded a $310,000 grant to study the treatment of eye disease.
One of the main focuses of the research is to treat diabetic retinopathy.
According to the American Academy of Ophthalmology, the disease is the leading cause of blindness among working Americans.
The study will evaluate whether a cellular therapy product by Arteriocyte could prevent the initial vaso-degenerative phase of the disease.
Related Videos
Related Content
